Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 33,596	$ 49,224
Prepaid expenses and other current assets	948	1,019
Total current assets	34,544	50,243
Long-term assets
Property and equipment, net	27	19
Operating lease right-of-use assets	558	124
Other long-term assets	40	15
Intangible assets, net	13,609	14,581
Total assets	48,778	64,982
Current liabilities
Accounts payable	3,348	3,489
Accrued compensation	652	1,005
Accrued clinical trial site costs	3,927	3,789
Operating lease liabilities	180	139
Other current liabilities	255	196
Total current liabilities	8,362	8,618
Long-term liabilities
Contingent liability for Essentialis purchase price	12,325	10,278
Operating lease liabilities, net of current	372
Total liabilities	21,341	19,435
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.001 par value, 250,000,000 shares authorized, 79,759,225 and 79,615,692 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively.	80	80
Additional paid-in-capital	229,744	227,912
Accumulated deficit	(202,387)	(182,445)
Total stockholders’ equity	27,437	45,547
Total liabilities and stockholders’ equity	48,778	64,982
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 282	$ 539